[cm_ad_changer group_id="1"]

Experimental Alzheimer’s drug could slow cognitive decline in patients, early results suggest

Eli Lilly and Company’s experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer’s disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday. View original article here Source

[cm_ad_changer group_id="2"]